Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review

Chia Tung Wu; Shy Chyi Chin; Pao Hsien Chu

doi:10.3389/fcvm.2022.856991

Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review

Chia Tung Wu, Shy Chyi Chin, Pao Hsien Chu^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

7 Scopus citations

Abstract

According to recent literatures, myocarditis is an uncommon side effect of mRNA vaccines against COVID-19. On the other hand, myocarditis after adenovirus based vaccine is rarely reported. Here we report a middle-aged healthy female who had acute fulminant perimyocarditis onset 2 days after the first dose of ChAdOx1 vaccine (AstraZeneca) without any other identified etiology. Detailed clinical presentation, serial ECGs, cardiac MRI, and laboratory data were included in the report. Possible mechanisms of acute myocarditis after adenoviral vaccine was reviewed and discussed. To our knowledge, a few cases of myocarditis after Ad26.COV2.S vaccine were reported, and this is the first case report after ChAdOx1 vaccine.

Original language	English
Article number	856991
Journal	Frontiers in Cardiovascular Medicine
Volume	9
DOIs	https://doi.org/10.3389/fcvm.2022.856991
State	Published - 21 04 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright © 2022 Wu, Chin and Chu.

Keywords

COVID-19
ChAdOx1
adenovirus
myocarditis
vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fcvm.2022.856991

Cite this

@article{4b7d5c977b8042078eae0660621527b7,

title = "Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review",

abstract = "According to recent literatures, myocarditis is an uncommon side effect of mRNA vaccines against COVID-19. On the other hand, myocarditis after adenovirus based vaccine is rarely reported. Here we report a middle-aged healthy female who had acute fulminant perimyocarditis onset 2 days after the first dose of ChAdOx1 vaccine (AstraZeneca) without any other identified etiology. Detailed clinical presentation, serial ECGs, cardiac MRI, and laboratory data were included in the report. Possible mechanisms of acute myocarditis after adenoviral vaccine was reviewed and discussed. To our knowledge, a few cases of myocarditis after Ad26.COV2.S vaccine were reported, and this is the first case report after ChAdOx1 vaccine.",

keywords = "COVID-19, ChAdOx1, adenovirus, myocarditis, vaccine",

author = "Wu, {Chia Tung} and Chin, {Shy Chyi} and Chu, {Pao Hsien}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Wu, Chin and Chu.",

year = "2022",

month = apr,

day = "21",

doi = "10.3389/fcvm.2022.856991",

language = "英语",

volume = "9",

journal = "Frontiers in Cardiovascular Medicine",

issn = "2297-055X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine

T2 - A Case Report and Literature Review

AU - Wu, Chia Tung

AU - Chin, Shy Chyi

AU - Chu, Pao Hsien

PY - 2022/4/21

Y1 - 2022/4/21

N2 - According to recent literatures, myocarditis is an uncommon side effect of mRNA vaccines against COVID-19. On the other hand, myocarditis after adenovirus based vaccine is rarely reported. Here we report a middle-aged healthy female who had acute fulminant perimyocarditis onset 2 days after the first dose of ChAdOx1 vaccine (AstraZeneca) without any other identified etiology. Detailed clinical presentation, serial ECGs, cardiac MRI, and laboratory data were included in the report. Possible mechanisms of acute myocarditis after adenoviral vaccine was reviewed and discussed. To our knowledge, a few cases of myocarditis after Ad26.COV2.S vaccine were reported, and this is the first case report after ChAdOx1 vaccine.

AB - According to recent literatures, myocarditis is an uncommon side effect of mRNA vaccines against COVID-19. On the other hand, myocarditis after adenovirus based vaccine is rarely reported. Here we report a middle-aged healthy female who had acute fulminant perimyocarditis onset 2 days after the first dose of ChAdOx1 vaccine (AstraZeneca) without any other identified etiology. Detailed clinical presentation, serial ECGs, cardiac MRI, and laboratory data were included in the report. Possible mechanisms of acute myocarditis after adenoviral vaccine was reviewed and discussed. To our knowledge, a few cases of myocarditis after Ad26.COV2.S vaccine were reported, and this is the first case report after ChAdOx1 vaccine.

KW - COVID-19

KW - ChAdOx1

KW - adenovirus

KW - myocarditis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85133185345&partnerID=8YFLogxK

U2 - 10.3389/fcvm.2022.856991

DO - 10.3389/fcvm.2022.856991

M3 - 文章

AN - SCOPUS:85133185345

SN - 2297-055X

VL - 9

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

M1 - 856991

ER -

Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this